OBJECTIVES: To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). METHODS: We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. RESULTS: Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. CONCLUSIONS: There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.
OBJECTIVES: To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). METHODS: We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. RESULTS: Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. CONCLUSIONS: There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.
Authors: T Kawahara; T Kin; S Kashkoush; B Gala-Lopez; D L Bigam; N M Kneteman; A Koh; P A Senior; A M J Shapiro Journal: Am J Transplant Date: 2011-08-29 Impact factor: 8.086
Authors: Srinath Chinnakotla; Gregory J Beilman; Ty B Dunn; Melena D Bellin; Martin L Freeman; David M Radosevich; Mustafa Arain; Stuart K Amateau; J Shawn Mallery; Sarah J Schwarzenberg; Alfred Clavel; Joshua Wilhelm; R Paul Robertson; Louise Berry; Marie Cook; Bernhard J Hering; David E R Sutherland; Timothy L Pruett Journal: Ann Surg Date: 2015-10 Impact factor: 12.969
Authors: J J Wilhelm; M D Bellin; T B Dunn; A N Balamurugan; T L Pruett; D M Radosevich; S Chinnakotla; S J Schwarzenberg; M L Freeman; B J Hering; D E R Sutherland; G J Beilman Journal: Am J Transplant Date: 2013-10-21 Impact factor: 8.086
Authors: Jaimie D Nathan; Yi Yang; Anne Eaton; Piotr Witkowski; Martin Wijkstrom; Matthew Walsh; Guru Trikudanathan; Vikesh K Singh; Sarah J Schwarzenberg; Timothy L Pruett; Andrew Posselt; Bashoo Naziruddin; Sri Prakash Mokshagundam; Katherine Morgan; Luis F Lara; Varvara Kirchner; Jin He; Timothy B Gardner; Martin L Freeman; Kate Ellery; Darwin L Conwell; Srinath Chinnakotla; Gregory J Beilman; Syed Ahmad; Maisam Abu-El-Haija; James S Hodges; Melena D Bellin Journal: Pancreatology Date: 2021-09-29 Impact factor: 3.996
Authors: Zachary R Bergman; Alexandria J Robbins; Fatima S Alwan; Melena D Bellin; Varvara A Kirchner; Timothy L Pruett; Kristine E Mulier; Alex A Boucher; Elizabeth R Lusczek; Greg J Beilman Journal: Pancreas Date: 2022-09-13 Impact factor: 3.243
Authors: Alexandria J Robbins; Elizabeth Lusczek; Melena D Bellin; Fatima S Alwan; James S Hodges; Scott A Chapman; Gregory J Beilman Journal: Pancreas Date: 2021-07-01 Impact factor: 3.243